<?xml version="1.0" encoding="UTF-8"?>
<fn-group>
 <fn id="d33e297">
  <p id="ntpara0010">Funder/Support: Work on this article was supported by 
   <funding-source id="gs1">
    <institution-wrap>
     <institution-id institution-id-type="doi">10.13039/100000002</institution-id>
     <institution>National Institutes of Health</institution>
    </institution-wrap>
   </funding-source> (NIH) grant R37-AI29168 (Dr Fleming).
  </p>
 </fn>
 <fn id="d33e306">
  <p id="ntpara0015">Dr DeMets is a consultant to the National Institutes of Health, the Food and Drug Administration and the pharmaceutical and medical device industry on the design, monitoring, and analysis of clinical trials. He receives compensation for serving on several industry sponsored data and safety monitoring committees including Astra Zeneca, AmgenAmgen, Actelion, Bristol Meyers Squib, DalCor, GSKGSK, MerckMerck, SanofiSanofi, Boston ScientificBoston Scientific, MedtronicMedtronic, Mesoblast, Intercept, Duke Clinical Research InstituteDuke Clinical Research Institute and Population Health ResearchHealth Research Institute of Hamilton. He holds no stock in any pharmaceutical or device company.</p>
 </fn>
 <fn id="d33e309">
  <p id="ntpara0020">Dr. Fleming reported receiving personal fees from industry sponsors for service on Data Monitoring Committees, research support from the National Institutes of Health, and extensive interactions in coronavirus disease 2019 (COVID-19) research with the World Health Organization Research and Development Working Group.</p>
 </fn>
</fn-group>
